chr19-4090589-C-A
Variant names:
Variant summary
Our verdict is Likely benign. The variant received -2 ACMG points: 2P and 4B. PM2BP4_Strong
The NM_030662.4(MAP2K2):c.*9G>T variant causes a 3 prime UTR change involving the alteration of a non-conserved nucleotide. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a benign outcome for this variant. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar.
Frequency
Genomes: not found (cov: 33)
Exomes 𝑓: 0.0 ( 0 hom. )
Failed GnomAD Quality Control
Consequence
MAP2K2
NM_030662.4 3_prime_UTR
NM_030662.4 3_prime_UTR
Scores
2
Clinical Significance
Not reported in ClinVar
Conservation
PhyloP100: -1.91
Publications
0 publications found
Genes affected
MAP2K2 (HGNC:6842): (mitogen-activated protein kinase kinase 2) The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, cognitive disability, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene. [provided by RefSeq, Jul 2008]
MAP2K2 Gene-Disease associations (from GenCC):
- cardiofaciocutaneous syndromeInheritance: AD Classification: DEFINITIVE, SUPPORTIVE Submitted by: Orphanet, ClinGen
- cardiofaciocutaneous syndrome 4Inheritance: AD Classification: DEFINITIVE, STRONG Submitted by: G2P, PanelApp Australia, Ambry Genetics, Genomics England PanelApp, Labcorp Genetics (formerly Invitae)
- neurofibromatosis-Noonan syndromeInheritance: AD Classification: SUPPORTIVE Submitted by: Orphanet
- Noonan syndromeInheritance: AD Classification: LIMITED Submitted by: ClinGen
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Likely_benign. The variant received -2 ACMG points.
PM2
Very rare variant in population databases, with high coverage;
BP4
Computational evidence support a benign effect (BayesDel_noAF=-0.86).
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
MAP2K2 | NM_030662.4 | c.*9G>T | 3_prime_UTR_variant | Exon 11 of 11 | ENST00000262948.10 | NP_109587.1 | ||
MAP2K2 | NM_001440688.1 | c.*9G>T | 3_prime_UTR_variant | Exon 9 of 9 | NP_001427617.1 | |||
MAP2K2 | NM_001440689.1 | c.*9G>T | 3_prime_UTR_variant | Exon 9 of 9 | NP_001427618.1 |
Ensembl
Frequencies
GnomAD3 genomes Cov.: 33
GnomAD3 genomes
Cov.:
33
GnomAD4 exome Data not reliable, filtered out with message: AC0 AF: 0.00 AC: 0AN: 1395910Hom.: 0 Cov.: 31 AF XY: 0.00 AC XY: 0AN XY: 688704
GnomAD4 exome
Data not reliable, filtered out with message: AC0
AF:
AC:
0
AN:
1395910
Hom.:
Cov.:
31
AF XY:
AC XY:
0
AN XY:
688704
African (AFR)
AF:
AC:
0
AN:
31548
American (AMR)
AF:
AC:
0
AN:
35728
Ashkenazi Jewish (ASJ)
AF:
AC:
0
AN:
25160
East Asian (EAS)
AF:
AC:
0
AN:
35754
South Asian (SAS)
AF:
AC:
0
AN:
79176
European-Finnish (FIN)
AF:
AC:
0
AN:
48272
Middle Eastern (MID)
AF:
AC:
0
AN:
4982
European-Non Finnish (NFE)
AF:
AC:
0
AN:
1077450
Other (OTH)
AF:
AC:
0
AN:
57840
GnomAD4 genome Cov.: 33
GnomAD4 genome
Cov.:
33
ClinVar
Not reported inComputational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_noAF
Benign
DANN
Benign
PhyloP100
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.